Company Overview
American Healthcare Capital is proud to be the exclusive representative for Project FamilyBridge, a confidential U.S. / Europe-based AI-native digital health platform focused on closing the care execution gap in pediatric chronic disease.
Project FamilyBridge is positioned as a family-centered pediatric CareOps platform that helps healthcare organizations support children and caregivers between visits, where much of pediatric care actually occurs. The platform addresses adherence routines, caregiver stress, health literacy, communication, nutrition, sleep, activity, school context and access barriers, converting between-visit signals into structured support, engagement workflows, and care-team visibility.
The Company combines a mobile-first digital support program with modular, role-specific empathic AI health agents that can be deployed through its own application or embedded into partner ecosystems. Current focus areas include type 1 diabetes, childhood obesity, and growth hormone disorders, with expansion potential into additional complex pediatric chronic care pathways, including oncology, autism and other high-need pediatric conditions.
Project FamilyBridge represents a timely opportunity for strategic acquirers, investors, and commercial partners seeking pediatric-specific AI capabilities, family-centered digital health infrastructure and workflow tools that can extend care teams without requiring linear staffing growth. The platform is designed to support families and care teams between visits, rather than replace clinicians or make autonomous clinical decisions.
Key Investment Highlights
- Family-centered pediatric CareOps platform creating a support layer between the home and the healthcare system, with the ability to translate family and between-visit signals into visit readiness, adherence follow-up, caregiver escalation, documentation support, and care-manager workflows.
- Purpose-built pediatric AI platform with modular, role-specific empathic AI agents designed for family support, navigation, caregiver coping, clinical liaison use cases, and partner-embedded deployment.
- Evidence-backed entry points across adherence, caregiver anxiety, self-management, obesity outcomes, and cultural adaptation, with reported outcomes across growth hormone therapy, type 1 diabetes, and childhood obesity initiatives.
- Flexible B2B / B2B2C commercialization model spanning providers, payers, life sciences, digital health / OEM partners, public programs, and practice workflow partnerships.
- Current traction includes approximately 600 families across active initiatives, four active institutional client or customer relationships, and an active pipeline of approximately $4 million across Life Sciences, obesity / cardiometabolic, oncology, digital health, public funding and institutional healthcare opportunities. Management expects operating reach to exceed 1,000 families in 2026 across pilots, deployments and sponsored programs.
- Financially, management’s 2026E model reflects approximately $1.3 million of total operating income / project-related revenue. The Company’s longer-range forecast assumes a transition toward recurring, multi-channel platform revenue beginning in 2027, driven by agentic platform pilots, validation activity and broader commercialization. These projections are execution-dependent and will be subject to diligence.
- Experienced founding and scientific team with digital health, health informatics, AI / ML, behavioral science, pediatric research, international commercialization, and clinical / research relationship depth across U.S. and European pediatric healthcare institutions.
- Project FamilyBridge is exploring strategic alternatives and is not being marketed as a distressed sale. The Company is seeking a strategic partner, investor or acquirer that can help accelerate scale through capital, distribution, compliance resources, evidence-generation support and customer-channel access.
Asking Price
The Company is being marketed on a price-to-be-determined basis, with valuation expected to be established through negotiations and discussions with qualified strategic and financial buyers.
The final transaction value is anticipated to be structured on a cash-free, debt-free basis and will exclude excess cash, accounts receivable, working capital adjustments, and any owned real estate unless otherwise negotiated by the parties.
The shareholders are open to retaining a meaningful equity position and partnering with a qualified buyer to support the continued growth and expansion of the Company.